TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38315777

Group type: EXPERIMENTAL
Intervention: Surgical treatment (specific type not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal fusion to the sacrum
Number of subjects: 0
Study: 38315832

Group type: EXPERIMENTAL
Intervention: 3L cellular immunotherapy after SOC (n=68)
Number of subjects: 359

Group type: COMPARATOR
Intervention: 3L therapy not receiving cellular immunotherapy after SOC (n=59)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: 3L chemotherapy after axi-cel (n=60)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: 3L cellular immunotherapy after axi-cel (n=8)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: 3L chemotherapy with SCT after salvage chemotherapy (n=10)
Number of subjects: 359

Group type: COMPARATOR
Intervention: 3L chemotherapy without SCT after salvage chemotherapy (n=50)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: 3L cellular immunotherapy after 2L axi-cel (n=8)
Number of subjects: 359
Study: 38315872

Group type: EXPERIMENTAL
Intervention: Single IV dose of 1080 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) dosing of 1080 mg on 3 consecutive days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intensive treatment with pegcetacoplan (IV or SC)
Number of subjects: 13
Study: 38315878

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 210

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 210
Study: 38315944

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.3 mg/m²
Number of subjects: 244

Group type: COMPARATOR
Intervention: Physician's choice chemotherapy
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 244
Study: 38315945

Group type: EXPERIMENTAL
Intervention: Cinpanemab (human-derived monoclonal antibody) administered intravenously every 4 weeks for 52 weeks
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 38315963

Group type: EXPERIMENTAL
Intervention: FULV + oxaliplatin (FOLFOX)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: 5-fluorouracil plus leucovorin (FULV)
Number of subjects: 1065
Study: 38315997

Group type: EXPERIMENTAL
Intervention: Behavioral science-informed, point-of-care, clinical decision support tools plus brief case-based education
Number of subjects: 371

Group type: COMPARATOR
Intervention: Brief case-based education alone
Number of subjects: 371
Study: 38316055

Group type: EXPERIMENTAL
Intervention: Clinically delivered laser power with assumed, homogeneous optical properties
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Clinically delivered laser power with measured, homogeneous optical properties
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patient-specific treatment planning using measured, homogeneous optical properties
Number of subjects: 13
Study: 38316133

Group type: EXPERIMENTAL
Intervention: Oral decitabine 35 mg plus cedazuridine 100 mg on days 1-5 and venetoclax (400 mg) for 14 days
Number of subjects: 39
Study: 38316224

Group type: EXPERIMENTAL
Intervention: Multisegmented esophageal fully covered self-expandable metal stent (FCSEMS)
Number of subjects: 23
Study: 38316236

Group type: EXPERIMENTAL
Intervention: Intraoperative dexamethasone followed by a 6-day oral methylprednisolone taper course
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intraoperative dexamethasone only (control group)
Number of subjects: 67
Study: 38316489

Group type: EXPERIMENTAL
Intervention: MSB11456
Number of subjects: 604

Group type: COMPARATOR
Intervention: EU-approved tocilizumab
Number of subjects: 604
Study: 38316493

Group type: EXPERIMENTAL
Intervention: NAVIGO 4LV 2D lead
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: NAVIGO 4LV ARC lead
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Both NAVIGO 4LV leads
Number of subjects: 217
Study: 38316587

Group type: EXPERIMENTAL
Intervention: Foot-ankle exercise programme alongside educational strategies
Number of subjects: 356

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 356
Study: 38316588

Group type: EXPERIMENTAL
Intervention: Daily oral dose of three strains of probiotics
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 450
Study: 38316595

Group type: EXPERIMENTAL
Intervention: Engagement with patient representatives and healthcare professionals to achieve consensus on core outcome set.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified-Delphi approach for consensus building.
Number of subjects: 0
Study: 38316600

Group type: EXPERIMENTAL
Intervention: Non-surgical weight loss
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 200
Study: 38316601

Group type: EXPERIMENTAL
Intervention: High-fibre legume-rich entrées for two meals/day in months 1-3 and one meal/day in months 4-6.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lean protein sources (e.g., chicken) replacing legumes in entrées.
Number of subjects: 60
Study: 38316738

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Surgical time
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Surgical approach
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Charlson scale
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists Classification
Number of subjects: 105
Study: 38316982

Group type: EXPERIMENTAL
Intervention: AMG 133 (maridebart cafraglutide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38317120

Group type: EXPERIMENTAL
Intervention: Hair cortisol concentration (HCC) in clinical sample
Number of subjects: 91
Study: 38317150

Group type: EXPERIMENTAL
Intervention: Problem-solving intervention for reducing sick leave among employees sick-listed due to common mental disorders.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 27
Study: 38317178

Group type: EXPERIMENTAL
Intervention: 5% albumin (12 mL/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 20% albumin (3 mL/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ringer-lactate (3:1 ratio to replace blood loss)
Number of subjects: 42
Study: 38317272

Group type: EXPERIMENTAL
Intervention: aXess Hemodialysis Graft
Number of subjects: 20
Study: 38317375

Group type: EXPERIMENTAL
Intervention: Glycine-powder air-polishing (GPAP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Full-mouth ultrasonic debridement (Fm-UD)
Number of subjects: 52
Study: 38317420

Group type: EXPERIMENTAL
Intervention: Subcutaneous blinatumomab
Number of subjects: 0
Study: 38317504

Group type: EXPERIMENTAL
Intervention: Recombinant porcine factor VIII (rpFVIII) 1-2 hours before surgery
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Recombinant porcine factor VIII (rpFVIII)
Number of subjects: 8
Study: 38317618

Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 9462
Study: 38318125

Group type: EXPERIMENTAL
Intervention: S48168 (ARM210) 120 mg daily for 29 days
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: S48168 (ARM210) 200 mg daily for 29 days
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: S48168 (ARM210)
Number of subjects: 7
Study: 38318236

Group type: EXPERIMENTAL
Intervention: Efgartigimod (10 mg/kg infusion per week for 4 weeks)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Efgartigimod
Number of subjects: 151
Study: 38318270

Group type: EXPERIMENTAL
Intervention: Heparin (3000-7500 U for vascular surgery, 27,500-40,000 U for cardiac surgery)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (5000 U subcutaneously)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3
Study: 38318484

Group type: EXPERIMENTAL
Intervention: 0.01% menthol solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo noncaloric solution
Number of subjects: 9
Study: 38318645

Group type: EXPERIMENTAL
Intervention: TIPIC syndrome patients
Number of subjects: 28
Study: 38318689

Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 38318703

Group type: EXPERIMENTAL
Intervention: Risk Assessment Model (RAM) embedded in the electronic health record
Number of subjects: 26506

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 26506
Study: 38318773

Group type: EXPERIMENTAL
Intervention: Primary care allied health treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hospital participants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Home participants
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Personal attention and support from primary care allied health professionals
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall treatment plan including physical exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Listening to the patient’s story and offering support
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration between primary care allied health professionals
Number of subjects: 30
Study: 38318789

Group type: EXPERIMENTAL
Intervention: WHO case definition for COVID-19 diagnosis
Number of subjects: 971
Study: 38318844

Group type: EXPERIMENTAL
Intervention: CYPWE
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sleep-Related Breathing Disorder scale of the Pediatric Sleep Questionnaire
Number of subjects: 72

Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 72
Study: 38318960

Group type: EXPERIMENTAL
Intervention: 3RP-NF (Relaxation Response Resiliency Program for NF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HEP-NF (Health Enhancement Program for NF)
Number of subjects: 0
Study: 38319147

Group type: EXPERIMENTAL
Intervention: BMS-986351
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-986351 combined with cetuximab and rituximab
Number of subjects: 0
Study: 38319178

Group type: EXPERIMENTAL
Intervention: Molnupiravir 200 mg, 400 mg, or 800 mg, twice daily for 5 days
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Molnupiravir (all doses combined)
Number of subjects: 304
Study: 38319179

Group type: EXPERIMENTAL
Intervention: Molnupiravir (combined group of 200, 400, or 800 mg)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 38319181

Group type: EXPERIMENTAL
Intervention: Surgery (partial meniscectomy or meniscal repair)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Exercise therapy and education (12-week supervised)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 121

Group type: COMPARATOR
Intervention: Exercise therapy and education
Number of subjects: 121
Study: 38319200

Group type: EXPERIMENTAL
Intervention: MV140 for 3 months
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MV140 for 6 months
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 38319212

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 38319214

Group type: EXPERIMENTAL
Intervention: Bentracimab
Number of subjects: 150
Study: 38319229

Group type: EXPERIMENTAL
Intervention: Heart failure treatment
Number of subjects: 0
Study: 38319239

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous aldesleukin (recombinant IL-2), 0.3 to 3.0 × 106 IU daily for 5 consecutive days (part A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous aldesleukin (recombinant IL-2), 1.5 and 2.5 × 106 IU daily for 5 consecutive days (part B)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 38319241

Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin (ZV) at doses of 0.5, 1.0, 1.5, 2.25, and 2.5 mg/kg every 3 weeks until cancer progression or unacceptable toxicity.
Number of subjects: 32
Study: 38319254

Group type: EXPERIMENTAL
Intervention: Reloxaliase
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 38319253

Group type: EXPERIMENTAL
Intervention: High-dose adeno-associated viral vector serotype 8 expressing ARSB
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low and intermediate dose cohorts of adeno-associated viral vector serotype 8 expressing ARSB
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (ERT)
Number of subjects: 9
Study: 38319255

Group type: EXPERIMENTAL
Intervention: ibrutinib-venetoclax
Number of subjects: 211

Group type: COMPARATOR
Intervention: chlorambucil-obinutuzumab
Number of subjects: 211
Study: 38319689

Group type: EXPERIMENTAL
Intervention: AMH cutoff of 3.2 ng/mL for the Elecsys AMH Plus or Elecsys AMH assays (Roche)
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: AMH measurement
Number of subjects: 1803
Study: 38319698

Group type: EXPERIMENTAL
Intervention: Data Health program (intervention)
Number of subjects: 8
Study: 38319800

Group type: EXPERIMENTAL
Intervention: Abiraterone (1000 mg once daily) plus olaparib (300 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abiraterone (1000 mg once daily) plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abiraterone and olaparib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abiraterone and placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall survival data
Number of subjects: 0
Study: 38319804

Group type: EXPERIMENTAL
Intervention: Infliximab continuation
Number of subjects: 115

Group type: COMPARATOR
Intervention: Infliximab discontinuation (placebo)
Number of subjects: 115
Study: 38319812

Group type: EXPERIMENTAL
Intervention: Sabizabulin (9 mg orally daily for up to 21 days)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 38319832

Group type: EXPERIMENTAL
Intervention: sFlt-1:PlGF ratio ≥40
Number of subjects: 1014

Group type: COMPARATOR
Intervention: sFlt-1:PlGF ratio <40
Number of subjects: 1014
Study: 38319837

Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m2 daily on days 1 to 3 every 28-day cycle)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Azacitidine (75 mg/m2 daily on days 1 to 3 every 28-day cycle)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m2 daily)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Azacitidine (75 mg/m2 daily)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Overall event-free survival
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 113
Study: 38319842

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg/day
Number of subjects: 111

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 111
Study: 38319849

Group type: EXPERIMENTAL
Intervention: SNM ON
Number of subjects: 124

Group type: COMPARATOR
Intervention: SNM OFF
Number of subjects: 124
Study: 38319851

Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: PVI+SM
Number of subjects: 324
Study: 38319850

Group type: EXPERIMENTAL
Intervention: Hypothermia at 33°C
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 2800
Study: 38319852

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses)
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1019
Study: 38319865

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 3425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3425
Study: 38319878

Group type: EXPERIMENTAL
Intervention: Oteseconazole 150 mg orally daily for 7 days, then once weekly for 11 weeks
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Oteseconazole
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Oteseconazole and Placebo
Number of subjects: 656
Study: 38319892

Group type: EXPERIMENTAL
Intervention: STRIDE (tremelimumab 300 mg, one dose plus durvalumab 1500 mg every 4 weeks)
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg every 4 weeks)
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 1171
Study: 38319896

Group type: EXPERIMENTAL
Intervention: Durvalumab plus gemcitabine and cisplatin
Number of subjects: 685

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine and cisplatin
Number of subjects: 685
Study: 38319910

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment using bioelectrical impedance analysis (BIA) throughout multimodal treatment.
Number of subjects: 0
Study: 38319937

Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA) for soil-transmitted helminths (STH)
Number of subjects: 0
Study: 38320013

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (33°C)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Therapeutic normothermia (36.8°C)
Number of subjects: 295
Study: 38320023

Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab (480 mg + 160 mg fixed-dose combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab (480 mg alone)
Number of subjects: 0
Study: 38320033

Group type: COMPARATOR
Intervention: Low-dose low-molecular-weight heparin thromboprophylaxis
Number of subjects: 1526

Group type: COMPARATOR
Intervention: Intermediate-dose low-molecular-weight heparin thromboprophylaxis
Number of subjects: 1526

Group type: COMPARATOR
Intervention: Low-dose plus aspirin
Number of subjects: 1526

Group type: COMPARATOR
Intervention: Therapeutic-dose anticoagulation
Number of subjects: 1526
Study: 38320035

Group type: EXPERIMENTAL
Intervention: QIV-HD
Number of subjects: 12477

Group type: COMPARATOR
Intervention: QIV-SD
Number of subjects: 12477
Study: 38320051

Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Radiotherapy with neoadjuvant androgen deprivation
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643
Study: 38320088

Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstructive gastrectomy
Number of subjects: 531

Group type: COMPARATOR
Intervention: Total gastrectomy
Number of subjects: 531

Group type: COMPARATOR
Intervention: Distal gastrectomy
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Females, BMI ≥23 kg/m2, No.12 lymph node dissection, adjuvant chemotherapy
Number of subjects: 531
Study: 38320097

Group type: EXPERIMENTAL
Intervention: Increased water intake (exact dosage and duration not specified)
Number of subjects: 0
Study: 38320098

Group type: EXPERIMENTAL
Intervention: Hypothermia (33.0°C)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Normothermia (36.8°C)
Number of subjects: 295
Study: 38320101

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Laparoscopic liver resection (LLR)
Number of subjects: 672
Study: 38320106

Group type: EXPERIMENTAL
Intervention: Early THA
Number of subjects: 11731

Group type: EXPERIMENTAL
Intervention: Early HA
Number of subjects: 11731
Study: 38320126

Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (ropeg; 100 μg every 2 weeks)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Phlebotomy only (standard therapy)
Number of subjects: 127
Study: 38320127

Group type: EXPERIMENTAL
Intervention: Cold static preservation at 10°C
Number of subjects: 70

Group type: COMPARATOR
Intervention: Matched controls (standard preservation)
Number of subjects: 70
Study: 38320128

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 4304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study: 38320129

Group type: EXPERIMENTAL
Intervention: Avapritinib 25 mg once daily
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 38320142

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg/day for 6 to 14 days)
Number of subjects: 2559

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2559

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 2559
Study: 38320144

Group type: EXPERIMENTAL
Intervention: Nalbuphine extended-release tablets (NAL ER) started at a dose of 27 mg once daily, titrated up to 162 mg twice daily at day 16.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nalbuphine extended-release tablets (NAL ER)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 38320143

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 5727

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 5727

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus 4 months of ADT
Number of subjects: 5727
Study: 38320155

Group type: EXPERIMENTAL
Intervention: 4-month regimen of rifampicin at 1800 mg/d (SR2)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: 4-month regimen of rifampicin at 1200 mg/d (SR1)
Number of subjects: 672

Group type: COMPARATOR
Intervention: 6-month control regimen
Number of subjects: 672
Study: 38320161

Group type: EXPERIMENTAL
Intervention: pegulicianine fluorescence-guided surgery (pFGS)
Number of subjects: 406
Study: 38320162

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 863

Group type: COMPARATOR
Intervention: Warfarin (target INR 2.0 to 3.0)
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 863

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 863
Study: 38320163

Group type: EXPERIMENTAL
Intervention: 109-miRNA saliva diagnostic signature for endometriosis
Number of subjects: 200
Study: 38320164

Group type: EXPERIMENTAL
Intervention: Participants with persistently detectable plasma EBV DNA
Number of subjects: 17838

Group type: EXPERIMENTAL
Intervention: Participants with transiently positive plasma EBV DNA
Number of subjects: 17838

Group type: EXPERIMENTAL
Intervention: Participants with persistently positive plasma EBV DNA
Number of subjects: 17838

Group type: COMPARATOR
Intervention: Participants with undetectable plasma EBV DNA in the first round
Number of subjects: 17838
Study: 38320181

Group type: EXPERIMENTAL
Intervention: Tezepelumab (210 mg every 4 weeks subcutaneously for at least 28 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 38320179

Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg twice daily for four cycles plus obinutuzumab administered in cycles 2 to 4
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vemurafenib plus obinutuzumab
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 30